CAMBRIDGE, Mass.–(BUSINESS WIRE)–Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Brian Riley as Senior Vice President of Technical Operations.
“I am tremendously excited to welcome Brian to our growing team,” said John Evans, chief executive officer of Beam. “Brian’s leadership will be invaluable to Beam as we progress our pipeline of base editing programs. Base editing represents a potential new class of genetic medicines that can offer an important new treatment option for patients suffering from serious diseases.”
Mr. Riley brings to Beam more than 20 years of biotech operational and manufacturing experience across diverse manufacturing modalities covering drug substance, drug product, and packaging, as well as facility design, construction and startup, and global multisite leadership. He joins Beam from Catalent Pharma Solutions, where he led the company’s biologics business over the past five years and managed five biologics plants across North America and Europe. Prior to Catalent, he served as the site director of Durham, NC operations at bioMerieux, where he led both the company’s compliance remediation effort and global growth platform. Before bioMerieux, he held progressive roles through quality and operations at Biogen Idec, Amgen and Diosynth Biotechnology. Mr. Riley holds an MBA from Campbell University and a B.S. from North Carolina State University.
“Throughout my career within the biotech industry, I have been fortunate to support a number of companies that have been successful in developing innovative technologies that benefit patients in need,” said Mr. Riley. “Since launching last year, the Beam team has made instrumental progress advancing its base editing technology and pipeline for the betterment of patients. Beam’s technology represents a tremendously exciting and novel approach to precision genetic medicine, and I am honored to join this talented team at this point in the company’s evolution.”
About Beam Therapeutics
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Beam is headquartered in Cambridge, Massachusetts. For additional information, visit www.BeamTx.com.
Contacts
Media:
Katie Engleman
1AB
katie@1abmedia.com
Investors:
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com